E2 - Endovascular Engineering
United States
- Menlo Park, California
- 09/04/2026
- Series C
- $80,000,000
Endovascular Engineering, Inc. ("E2"), is a mission driven, venture-backed company focusing on the development and deployment of groundbreaking clot removal technologies that target venous thromboembolism.
- Industry Medical Equipment Manufacturing
- Website https://endovascularengineering.com/
- LinkedIn https://www.linkedin.com/company/endovascular-engineering/
Related People
Dan RoseFounder
Switzerland -
Lausanne, Vaud
With over 20 years of leadership in medtech, currently serving as CEO of E2 as well as Chairman of the Board at UroMems and Lymphatica Medtech. Brings expertise in company leadership, board administration and strategic growth to advance innovative medical technologies. Passionate about fostering organizational success through collaborative leadership and a mission-driven approach to improve healthcare outcomes. Excels in aligning teams with organizational goals and delivering impactful solutions in rapidly evolving markets.
Golden Analytics | $7,000,000 | (Apr 9, 2026)
HexemBio | $10,400,000 | (Apr 9, 2026)
E2 - Endovascular Engineering | $80,000,000 | (Apr 9, 2026)
True Footage | $40,000,000 | (Apr 9, 2026)
Aria Networks, Inc. | $125,000,000 | (Apr 9, 2026)
Trent AI | $13,000,000 | (Apr 9, 2026)
GoSats - The simplest onramp to Digital Assets in India | $5,000,000 | (Apr 9, 2026)
Life Biosciences | $80,000,000 | (Apr 9, 2026)
Noon | $44,000,000 | (Apr 7, 2026)
Miravoice | $6,300,000 | (Apr 7, 2026)